Initial Therapeutics is discovering and developing a new class of small-molecule medicines designed to halt pathogenic protein formation in the earliest stages.
Initial’s approach is unique and starkly differentiated from protein degradation and other interventions that recognize and tackle proteins only after they have been fully formed.
Initial’s approach is unique and starkly differentiated from protein degradation and other interventions that recognize and tackle proteins only after they have been fully formed.
Location: United States, California, South San Francisco
Employees: 1-10
Total raised: $75M
Founded date: 2020
Investors 1
| Date | Name | Website |
| - | Apple Tree... | appletreep... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 01.05.2023 | Series A | $75M | Apple Tree... |
Mentions in press and media 7
| Date | Title | Description |
| 25.03.2025 | Daniel Pierce Joins Initial Therapeutics as Chief Scientific Officer | SOUTH SAN FRANCISCO, Calif., March 24, 2025 — Initial Therapeutics, a life sciences company discovering and developing new small-molecule therapeutics with a novel platform to selectively modulate translation of pathogenic proteins by the r... |
| 18.04.2024 | Initial Therapeutics Names Peter DiLaura as CEO | SOUTH SAN FRANCISCO, Calif., April 18, 2024 (PR NEWSWIRE) – Initial Therapeutics Inc., a life sciences company discovering and developing new small-molecule therapeutics with a novel platform to selectively modulate translation of pathogeni... |
| 01.05.2023 | Initial Therapeutics Raises $75M in Series A Funding | Initial Therapeutics, a South San Francisco, CA-based biotechnology company, raised $75m in Series A funding. Apple Tree Partners created the company and made the initial investment. Co-founded by Jamie H.D. Cate, Ph.D., Professor of Chemis... |
| 01.05.2023 | Initial Therapeutics Raises $75M Series A Funding | SOUTH SAN FRANSICO, CA, Initial Therapeutics was created by ATP with $75M in Series A funding. >> Click here for more funding data on Initial Therapeutics >> To export Initial Therapeutics funding data to PDF and Excel, clic... |
| 01.05.2023 | With $75 Million from Apple Tree Partners, Initial Therapeutics Launches to Create a New Kind of Drug Designed to Stop the Formation of Difficult-to-Drug Protein Targets | Initial was created to take on undruggable disease-causing proteins by discriminately intercepting their translation in the exit tunnel of the ribosome Initial’s platform brings together scientific breakthroughs from the labs of Jamie H.D.... |
| 01.05.2023 | With $75 Million from Apple Tree Partners, Initial Therapeutics Launches to Create a New Kind of Drug Designed to Stop the Formation of Difficult-to-Drug Protein Targets | Initial was created to take on undruggable disease-causing proteins by discriminately intercepting their translation in the exit tunnel of the ribosome |
| - | Initial Therapeutics | “Initial Therapeutics, an ATP company, is discovering and developing a new class of small-molecule medicines designed to prevent pathogenic protein synthesis.” |